NMRA

Rating neutralAI Memo

Neumora Therapeutics

As of 2026-06-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

NMRA-898 Phase 1 data in schizophrenia • 2026-10-31

Base target: $1 / p=45% prob

Biggest risk

The bear case is that the company has lost its most advanced program after three late-stage MDD misses, has moved into a restructuring posture, and must now re-earn credibility with earlier-stage assets in difficult CNS indications; low coverage and missing verified post-event estimate revisions keep visibility poor.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The bullish case is now almost entirely balance-sheet-plus-optional-pipeline: management still points to runway into the third quarter of 2027, and NMRA-511, NMRA-898, and NMRA-215 together give the company multiple shots at rebuilding value if one of the remaining programs shows credible data [#SEC-8K-2026-05-07] [#8-K-2026-06-15].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-06-18

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-navacaprant reset and August pipeline/runway update
NMRA-511 dose-expansion completion and Phase 2b start setup
The bullish case is now almost entirely balance-sheet-plus-optional-pipeline: management still points to runway into the third quarter of 2027, and NMRA-511, NMRA-898, and NMRA-215 together give the company multiple shots at rebuilding value if one of the remaining programs shows credible data [#SEC-8K-2026-05-07] [#8-K-2026-06-15].

BearKey bullets

A June 10, 2026 loan amendment changed the interest-only period and introduced a minimum-liquidity covenant effective July 1, 2026, adding financing and covenant-monitoring risk if market cap or operational milestones weaken [#8-K-2026-06-15].
Cash runway is guided into the third quarter of 2027, but the equity story now depends on earlier-stage readouts from NMRA-511, NMRA-898, and NMRA-215, which carry typical small-cap biotech binary risk [#SEC-8K-2026-05-07] [#8-K-2026-06-15].
Navacaprant has been discontinued after KOASTAL-2 and -3 failed to achieve statistical significance on primary and key secondary endpoints, removing the former lead late-stage asset [#8-K-2026-06-15].

WatchKey bullets

NMRA-898 Phase 1 data in schizophrenia

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +118% / -59%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

Tone turned sharply negative after the June 15, 2026 Phase 3 miss and program discontinuation. Trade-press coverage described an immediate roughly 45%-50% selloff, which is directionally consistent with the reset from a lead-asset failure, but the packet still lacks verified post-event analyst revision breadth, options color, or usable social coverage, so this remains a low-conviction monitoring name rather than a thesis with strong positive revision support.

As of 2026-06-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-navacaprant reset and August pipeline/runway update
NMRA-511 dose-expansion completion and Phase 2b start setup

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-06-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

20.00

Social Sentiment (7d)

50.00

Events

Other notable items detected

EVENT2026-10-31
NMRA-898 Phase 1 data in schizophrenia
Management has said NMRA-898 Phase 1 data are expected in the second half of 2026; with navacaprant gone, even early proof of CNS penetration, tolerability, and doseability matters more for the equity narrative than it did before June [#SEC-8K-2026-05-07] [#8-K-2026-06-15].
Prob 65.00% • Move 28.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Post-navacaprant reset and August pipeline/runway update
2026-08-15
After KOASTAL-2 and -3 missed the primary and key secondary endpoints, Neumora discontinued navacaprant, cut roughly 35% of staff, guided to about $10 million of annualized savings with about $2 million of one-time restructuring cost, and said NMRA-215 would get a program update with second-quarter results in August 2026; the next update must show the company can preserve runway while re-centering the story on the remaining pipeline [#8-K-2026-06-15] [#SEC-8K-2026-05-07].
Prob 85% • Move 18% • Priced-in 75%

Long-term Catalysts

Months to a year

NMRA-511 dose-expansion completion and Phase 2b start setup
2026-12-31
Neumora now frames NMRA-511 as a lead value driver, with completion of the higher-dose multiple-ascending-dose cohort targeted for the fourth quarter of 2026 and those data intended to inform a Phase 2b study by year-end; positive execution could partly rebuild confidence, but this is still an early-stage neuroscience asset after a major Phase 3 failure elsewhere in the portfolio [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-07] [#8-K-2026-06-15].
Prob 60% • Move 35% • Priced-in 20%

Risks

A June 10, 2026 loan amendment changed the interest-only period and introduced a minimum-liquidity covenant effective July 1, 2026, adding financing and covenant-monitoring risk if market cap or operational milestones weaken [#8-K-2026-06-15].
Cash runway is guided into the third quarter of 2027, but the equity story now depends on earlier-stage readouts from NMRA-511, NMRA-898, and NMRA-215, which carry typical small-cap biotech binary risk [#SEC-8K-2026-05-07] [#8-K-2026-06-15].
Navacaprant has been discontinued after KOASTAL-2 and -3 failed to achieve statistical significance on primary and key secondary endpoints, removing the former lead late-stage asset [#8-K-2026-06-15].
The company is reducing its workforce by about 35%, which lowers spend but also raises execution risk as remaining programs move forward [#8-K-2026-06-15].

Peers

Symbol	Summary
RCKT	Clinical-stage biotech peer useful for framing binary readout risk and rerating behavior after pivotal or near-pivotal events, though the mechanism and disease mix differ.
RZLT	Small-cap biotech comparator where valuation is highly event-driven and sensitive to pipeline timing, funding perception, and credibility after development setbacks.
FENC	Loose small-cap biotech peer for runway sensitivity and catalyst-trading behavior rather than commercial execution or direct indication overlap.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-18

Loading AI feed…

Symbol

Summary

RCKT

Clinical-stage biotech peer useful for framing binary readout risk and rerating behavior after pivotal or near-pivotal events, though the mechanism and disease mix differ.

RZLT

Small-cap biotech comparator where valuation is highly event-driven and sensitive to pipeline timing, funding perception, and credibility after development setbacks.

FENC

Loose small-cap biotech peer for runway sensitivity and catalyst-trading behavior rather than commercial execution or direct indication overlap.